Men with castration-resistant prostate cancer who have previously received diethylstilboestrol treatment can still benefit from abiraterone, according to the results of a new study. In a cohort of 247 patients who received abiraterone, 114 (41.6%) men were found to have previously received diethylstilboestrol. The proportion of patients who experienced ≥50% PSA decline were similar for men who had and had not received diethylstilboestrol, in both the prechemotherapy (74.1% versus 85.4%) and postchemotherapy (28.4% versus 35.4%) settings.
ORIGINAL RESEARCH PAPER
Omlin, A. et al. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. Br. J. Cancer doi:10.1038/bjc.2013.446
Rights and permissions
About this article
Cite this article
Abiraterone active after diethylstilboestrol treatment. Nat Rev Urol 10, 556 (2013). https://doi.org/10.1038/nrurol.2013.192
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2013.192